Sartorius Stedim Biotech S.A. (56S1)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 211.00 |
|---|---|
| 52-week range | 151.50 – 223.50 |
| Return, 1 month / 3 months | +2.7% / +31.5% |
| Return, 1 year / 3 years | +0.1% / +28.7% |
| Trend | Uptrend |
| RSI (14) | 51 |
| Volatility (1 year) | 38.2% |
| Worst drawdown (1 year) | -31.9% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | 0.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sartorius Stedim Biotech S.A. supplies equipment and services used in the manufacture of biopharmaceuticals. The company makes single-use bioreactors, filtration systems, tubing, bags and other disposable components, along with instruments and validation support. Its customers are pharmaceutical and biotechnology companies that produce medicines from living cells, including vaccines and therapeutic proteins. Sartorius Stedim Biotech is based in Aubagne, France, and operates as part of the wider Sartorius group, serving laboratories and production sites around the world.
Sartorius Stedim Biotech S.A. trades under the code 56S1 on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sartorius Stedim Biotech S.A. (56S1) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 211.00 on 23 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 302 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.1% and over the last three months it rose 31.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 84 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.7% | ||
| From 52-week high | -5.6% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 31.5% | ||
| 6-month return | 13.3% | ||
| 12-month return, skipping the last month | -2.5% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -31.9% | ||
| Liquidity | 22 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 6.7% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −3.2% |
|---|---|
| 1 month | +2.7% |
| 3 months | +31.5% |
| 6 months | +13.3% |
| 1 year | +0.1% |
| 3 years | +28.7% |
| 5 years | +372.0% |
Signals
| 50-day / 200-day average | 202.62 / 182.39 |
|---|---|
| Golden / death cross (60 days) | Golden, 31 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.09 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Mar 2026 | EUR 0.6900 |
| 2 Apr 2025 | EUR 0.6900 |
| 2 Apr 2024 | EUR 0.6900 |
| 30 Mar 2023 | EUR 1.4400 |
| 31 Mar 2022 | EUR 1.2600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.